Nucleic Acid Therapeutics CDMO Market is expected to Observe Considerable Growth Opportunities to 2031

Nucleic Acid Therapeutics CDMO Market worth $4.69 Bn by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Nucleic Acid Therapeutics CDMO Market By Technology (Column-Based Method and Microarray-Based Method), Products (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, and Other Services), End-users (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories) Chemical Synthesis (Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis) - By Trends, Industry Competition Analysis, Revenue and Forecast Till 2030"
InsightAce Analytic, most Recent research indicates that the global nucleic acid therapies CDMO market was valued at US$ 1.93 billion in 2021 and is projected to grow at a promising CAGR of 10.7% from 2022to 2030, reaching US$ 4.69 billion.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1348

Numerous genetic abnormalities are commonly treated with nucleic acid therapies. The The need for nucleic acid therapeutic applications is growing due to the significant frequency of hereditary and chronic disorders. Deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or other similar chemical substances serve as the foundation for nucleic acid treatments. In order to increase their investment in the production of nucleic acid-based medicines, the manufacturers in this sector are entering into new alliances, agreements, collaborations, mergers, and business expansions with the contract development and manufacturing company (CDMO). Ajinomoto Co., Inc. and OmniChem NV ("OmniChem"), for example, inked a deal in December 2016 to purchase all of GeneDesign, Inc.'s shares, a major Japanese contract development and manufacturing organization (CDMO1) for nucleic acid medications. The Company's expansion in the CDMO market for nucleic acid medications will be accelerated by this acquisition.
The market is expected to grow during the forecast years due to factors likethe growing demand for mRNA-based novel therapies, rising healthcare costs, manufacturing cost reduction at CDMOs, an increase in nucleic acid drug approvals, and the rapid adoption of advanced nucleic acid technologies for disease diagnosis and treatment. However, obstacles include supply chain and targeted delivery challenges, maintaining efficacy and minimizing off-target toxicity, and a lack of nucleic acid production knowledge would limit the market's growth.
to rising R&D activity, the emergence of new competitors, and the high demand for nucleic acid therapies-primarily as a result of the COVID-19 pandemic and improved reimbursement practices in the region-North America is market with the fastest rate of regional growth. other hand, the Asia Pacific nucleic acid therapies CDMO market is anticipated to rise faster due to the rising incidence of genetic disorders, expanding biopharmaceutical companies, and improvements in medical technology.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Major key players in the nucleic acid therapeutics CDMO market are Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG., Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc, QIAGEN N.V., S.T. Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation, Laboratorios Farmacéuticos Rovi, S.A., Sartorius AG (BIA Separations), AGC Biologics, FUJIFILM Diosynth Biotechnologies, Hanmi Pharmaceutical, Arranta Bio (Recipharm), ST Pharm, BioCina Pty Ltd., Curia Global, Inc. and Other Prominent Players.

Key Industry Developments:
• In June 2022, Merck agreed with Agilent Technologies to develop Process Analytical Technologies (PAT). Merck and Agilent Technologies are filling a void in the downstream PAT market through this partnership. Merck expands real-time monitoring and automated process control of key process parameters (CPPs) and critical quality attributes (CQAs) to downstream processing through the combination of its bioprocess portfolio with Agilent Technologies' sophisticated analytical technologies.
• In June 2022, CordenPharma expanded its xRNA capabilities at its Caponago, Italy, plant for sterile injectables. The business claims to have invested over €10 million in a new formulation, research, and manufacturing areas for Lipid Nanoparticles (LNP). The expansion will help clients go from pre-clinical to clinical development of xRNA-based treatments (mRNA, siRNA, saRNA, microRNA, etc.), accelerating the delivery of their new medicinal solutions into clinical stages and beyond.
• In Feb 2022, Recipharm has acquired Arranta Bio. The acquisition is a cornerstone of Recipharm's strategy to provide scientifically differentiated contract development and manufacturing services for ATMPs to innovative drug developers in the Biologics market. It builds on the capabilities acquired through the recently announced GenIbet transaction and the acquisition of Vibalogics.
• In June 2021, Danaher Corporation announced that it would add protein production, plasmid DNA, and mRNA services to its bulging life sciences portfolio by acquiring Aldevron. Through the acquisition, Danaher adds contract manufacturing services.
• In August 2020, Agilent Technologies Inc. announced it would extend its advanced production facility in Frederick, Colorado, that develops and produces "oligos," which are short DNA and RNA molecules used to make nucleic acid-based therapeutics. Oligos hold the potential to be used in inventing treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases, and other conditions. The expansion has increased the current capacity for manufacturing therapeutic oligos at the Frederick site.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1348

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Technology
• Column-Based Method
• Microarray-Based Method
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Products
• Standard Nucleic Acid
• Micro-Scale Nucleic Acid
• Large-Scale Nucleic Acid
• Custom Nucleic Acid
• Modified Nucleic Acid
• Primers
• Probes
• Other Nucleic Acid
• Other Services
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Chemical Synthesis
• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on End-Users
• Pharmaceutical Companies
• Academic Research Institute
• Diagnostic Laboratories
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada
Europe Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1348

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.